Determination of an effective dose of eltenac and its comparison with that of flunixin meglumine in horses after experimentally induced carpitis

Author:

Hamm D.1,Turchi P.1,Johnson J. C.1,Lockwood P. W.1,Thompson K. C.1,Katz T.1

Affiliation:

1. From Research for Animal Health, Fayetteville, AR 72701 (Hamm, Turchi) and Schering-Plough Animal Health, Union, NJ 07083-1982 (Johnson, Lockwood, Thompson, Katz).

Abstract

Abstract Objectives To titrate a clinically effective eltenac dosage (0.1, 0.5, and 1.0 mg/kg of body weight), compared with vehicle only, and to compare efficacy of the most effective eltenac dosage with that of 1.1 mg of flunixin meglumine/kg. Animals 40 healthy horses, ranked after model induction on the basis of lameness severity, were randomly assigned to 5 treatment groups, with 4 replicates of 10 horses each. Procedure On day -5, after surgical preparation of the left carpal region, 0.7 ml of Freund's complete adjuvant was injected into the intercarpal space. Horses were observed daily, from the day of carpitis induction to day 0, when stride length was used as the method of ranking horses for randomization to treatment assignment. Treatments were administered IV once daily for 3 consecutive days, starting on day 0. Prior to carpitis induction on day -5, and at time 0 (pretreatment). 2, 4, 12, 24, 36. 48, 60, 72, and 96 hours after treatment initiation, resting respiratory rate and pulse, rectal temperature, carpal circumference, carpal flexion angle, stride length, carpal hyperthermia, and signs of carpal pain were recorded. Results Compared with the vehicle and 0.1 mg of eltenac/kg, 0.5 and 1.0 mg/kg caused statistically significant improvements (ie, reduction of carpal circumference, increase in carpal flexion angle, and increase in stride length of the affected limb), but values did not differ significantly between the 2 dosages. Thus, a dose-response plateau for eltenac was reached at 0.5 mg/kg. Comparison with flunixin meglumine at a dosage of 1.1 mg/kg did not indicate significant differences between the 2 treatment groups at the pivotal time of 96 hours for carpal circumference, carpal flexion angle, stride length, carpal hyperthermia, and signs of carpal pain. Adverse reactions were not observed. Clinical Relevance Under conditions of this study, a dosage plateau for eltenac was determined (0.5 mg/kg) that was statistically equivalent to eltenac (1.0 mg/kg) and flunixin meglumine (1.1 mg/kg) in a 3-day IV dosing regimen. (Am J Vet Res 1997;58:298–302)

Publisher

American Veterinary Medical Association (AVMA)

Cited by 19 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Medical Therapy in Equine Wound Management;Veterinary Clinics of North America: Equine Practice;2018-12

2. Non‐steroidal Anti‐inflammatories;Equine Clinical Immunology;2015-11-06

3. Pharmacotherapy of joint and tendon disease;Equine Sports Medicine and Surgery;2014

4. Pharmacokinetics and Effects of Alkalization after Intravenous Administration of Eltenac in Horses;Journal of Equine Veterinary Science;2013-12

5. Dose titration of the clinical efficacy of intravenously administered flunixin meglumine in a reversible model of equine foot lameness;Equine Veterinary Journal;2012-11-27

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.7亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2025 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3